v3.25.2
BASIS OF PRESENTATION (Details)
3 Months Ended
May 31, 2025
item
BASIS OF PRESENTATION  
Percentage of outstanding stock owned by the President and Chairman of the Board 81.00%
Number of antineoplaston drugs that have received FDA approval 0